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1,3-Butadiene (BD), C4H6 (CAS No. 106-
99-0), is a major raw material used in petro-
chemical manufacturing to make synthetic
butyl rubber, coatings, and acrylonitrile-1,3-
butadiene-styrene (ABS) plastics (1).
Exposure to BD occurs mainly via inhalation
because it is a gas at room temperature. In
1990, approximately 65,000 workers were
likely exposed to BD in the United States
(2). Additionally, BD can also be found in
urban air pollution, gasoline vapor, and ciga-
rette smoke (3). Animal inhalation studies
have indicated that BD is a multiple-organ
carcinogen in Sprague-Dawley rats and in
B6C3F1 mice (4,5). With growing concerns
about the potential risks to humans from
exposure to BD, numerous epidemiologic
studies of occupational workers exposed to
BD have been performed. However, ﬁndings
regarding BD carcinogenicity in humans
have been equivocal, perhaps partly because
reliable exposure assessment is lacking (6–9). 
Understanding of the relationship
between external exposure and internal
dose is critical for determining a clear quan-
titative exposure–disease relationship (10);
therefore, it is essential to characterize the
influential factors determining the external
exposure–internal dose association in
humans. Physiologically based pharmacoki-
netic (PBPK) simulation models have sug-
gested that physiologic parameters such as
respiratory ventilation and the blood:air
partition coefﬁcient are critical in determin-
ing human internal dose to airborne pollu-
tants (11,12). The blood:air partition
coefﬁcient is an indicator of blood solubility
of a volatile chemical, and is one of the most
important properties in the respiratory
uptake of gases in humans (13). Relevant
human data are very limited; most of the
toxicokinetic information on BD has been
obtained either from model simulations or
extrapolation of the results of animal studies
(14,15). However, the adequacy of such
extrapolation to humans exposed to low
concentrations of BD is of concern. The tox-
icokinetics of BD at high exposure concen-
tration levels are different from those at low
levels and there are interspecies differences in
the kinetic pathways of BD (16–18). 
The main objective of the present
human inhalation study was to explore inﬂu-
ential physiologic factors that determine the
respiratory uptake of BD. Uptake is one of
the rate-limiting steps for the internal dose.
Individuals with low uptake cannot produce
large amounts of toxic metabolites, whereas
those with high uptake may or may not do
so, depending upon their metabolic rates.
Physiologic parameters examined in this
study included the blood:air partition coefﬁ-
cient of BD, alveolar ventilation, sex, age,
and race. Two potential additional factors that
may affect metabolism, alcohol consumption
and smoking, were also incorporated into the
statistical analyses to estimate the associa-
tions of interest. Evaluation of these factors
may lead to more reliable exposure assess-
ment work and epidemiologic studies, and
further our understanding of factors affect-
ing the exposure–disease relationships in
humans. 
Methods and Materials
Study subjects. Subjects were recruited from
the Longwood Medical Area of Boston
between 1997 and 1999. They were tested
using a human subject protocol approved by
the Human Subjects Committee of the
Harvard School of Public Health. Before they
gave consent, they were informed that BD is a
suspected human carcinogen, that the experi-
mental exposure was within the range of pos-
sible everyday exposures, and that the
experimental exposure might cause a small
increase in their lifetime risk of cancer, possi-
bly leukemia. We estimated that this expo-
sure would cause less than a one per million
increase in lifetime risk of leukemia, using
the California Environmental Protection
Agency (EPA) Air Resources Board risk
assessment, which was based on the mouse as
the most sensitive species (19). The aim of
subject recruitment was to test an approxi-
mately balanced number of males and
females from four major U.S. population
groups: Caucasian, African-American,
Hispanic, and Asian groups. All participants
were interviewed before testing to ensure that
they had no metabolic or cardiovascular dis-
eases, nor were planning to start a pregnancy
in the succeeding 6 months.
Experimental procedures and conditions.
Before starting the experiment, we verified
each subject’s health and obtained informed
consent. We then administered a standard-
ized questionnaire to collect demographic
and lifestyle information such as age, sex,
racial background, medical history, smoking
status, and alcohol consumption. Smoking
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1,3-Butadiene (BD), a suspected human carcinogen, is used as the raw material in industries to
make synthetic butyl rubber and plastics. Simulation models using experimental animal data have
shown that physiologic factors play an important role in the kinetic behavior of BD. However,
human data are limited. The aim of this inhalation study was to identify inﬂuential human physi-
ologic factors in the respiratory uptake of BD. We recruited 133 healthy volunteers in Boston,
Massachusetts, into this study and tested them under an approved human subjects protocol. Each
subject was exposed to 2 ppm (4.42 mg/m3) BD for 20 min, followed by puriﬁed air for another
40 min. Five exhaled breath samples collected during exposure were used to determine the respi-
ratory uptake of BD, which was defined as absorbed BD (micrograms) per kilogram of body
weight during exposure. Although subjects were given identical administered doses (40
ppm/min), there was a wide range of uptake, 0.6–4.9 µg/kg. Of the studied physiologic factors,
the blood:air partition coefficient and alveolar ventilation were most significant in determining
the respiratory uptake (p < 0.001 for each). In addition, in the multiple regression analysis,
females had significantly higher respiratory uptake of BD than males on a weight basis. For all
subjects, increasing age and cigarette smoking led to signiﬁcantly decreased respiratory uptake of
BD. The results of this human study are consistent with previous kinetic simulations and animal
studies. The ﬁndings also suggest that interindividual variation in human physiologic factors that
affect the exposure–internal dose relationship should be considered while also exploring expo-
sure–disease associations in future epidemiologic research. Key words: alveolar ventilation,
blood:air partition coefficient, 1,3-butadiene, human, physiologic, respiratory uptake, sex.
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(Yes/No). Alcohol consumption was catego-
rized as no drinking habit, 1 to 2 drinks
weekly, or more than 2 weekly drinks. The
deﬁnition of a drink was deﬁned as 12 oz of
beer, 5 oz of wine, or 1.5 oz of hard liquor
(20). Each subject chose an optimal size of
breathing mask (small, medium, or large;
Hans Rudolph, Inc., Kansas City, MO) to
comfortably ﬁt his or her own face. The sub-
jects checked for mask leaks by placing the
palms of hands over the mask’s valves and
breathing in for 10 sec to ensure the mask ﬁt
snugly without leaks. One minute of breath-
ing or 6 breaths were collected through the
breath sampling system into an 8-L spirome-
ter (Warren E. Collins, Braintree, MA) to
calibrate the RespiTrace breathing monitor
(NIMS, Inc., Miami Beach, FL). As a result
of operating problems with the RespiTrace,
28 subjects (20%) were not monitored;
instead, data from spirometer calibrations
(number/min and tidal volume) and exhaled
volume in breath samples (volume in 1 min)
were used. We collected a baseline breath
sample before exposure to verify there were
no background BD sources to interfere with
the experiment. We also collected a venous
blood sample before beginning the inhala-
tion experiment to determine the blood:air
partition coefﬁcient.
Each subject was exposed to 2.0 ppm
(4.42 mg/m3) BD for 20 min, followed by
charcoal puriﬁed air for another 40 min with
an inhalation exposure system developed by
Lin and coworkers (21). We collected 10
timed breath samples from each volunteer at
2, 5, 10, 15, 19, 21, 22, 28, 38, and 58 min
from the start of exposure. We chose the
time points on the basis of an optimized
sampling time schedule developed by Bois
and coworkers (22); each of the first seven
breath samples was collected for 1 min, and
the last three were collected for 2 min each
to increase the sensitivity of detecting
exhaled BD. We used exhaled breath sam-
ples collected during exposure (wash-in
phase) to determine the respiratory uptake of
BD. We used these breath samples and other
measured population parameters to develop
the personalized physiologically based phar-
macokinetic (PBPK) model and to study the
elimination of BD and excretion of urine
BD metabolites (23). 
Determination of alveolar BD, alveolar
ventilation, and respiratory uptake of BD.
Total uptake of gas/vapor traditionally has
been determined as the difference between
the total amount of inhaled and exhaled gas
during the exposure (24,25). In this study,
we reported respiratory uptake of BD as the
absorbed BD micrograms per kilogram of
body weight to reﬂect the body burden on a
unit weight basis (5,26,27). This was the
variable used for statistical analyses in the
study. Total amount of inhaled BD was cal-
culated as the inhaled concentration times
the alveolar ventilation times the duration of
exposure. Alveolar ventilation was used
because the pulmonary minute ventilation
includes mixed exhaled breath that contains
both alveolar (end-tidal) gas and inhaled gas
from the respiratory dead space where there
is no gas exchange. Thus the BD concentra-
tion in mixed exhaled breath is a function of
both the inhaled and the alveolar BD con-
centrations as given in Equation 1:
[1]
where BDmixed = mixed exhaled BD concen-
tration in parts per million; BDalveolar = alve-
olar BD concentration in parts per million;
BDdead space = inhaled BD concentration in
parts per million; tidal volume = average
tidal volume in each breath (milliliters per
breath); and total dead space = sum of indi-
vidual physiologic dead space volume and
mask dead space volume in each breath (mil-
liliters per breath). We used Equation 1 to
estimate the alveolar concentration from
measured quantities. Pulmonary minute
ventilation is the sum of alveolar and dead
space ventilation, as shown in Equation 2. 
V
·
E = V
·
A+ (breathing frequency)
× (total dead space) [2]
where V
·
E = pulmonary minute ventilation
(liters per minute); V
·
A = alveolar ventilation
(liters per minute); breathing frequency =
breaths every minute (breaths per minute);
and total dead space = sum of individual
physiologic dead space and mask dead space
in each breath (milliliters per breath). We
used the relationship in Equation 2 to esti-
mate the alveolar ventilation rate, V
·
A.
Dead space in this system comes from
two sources: inside the face mask and in the
airways of the subject. The dead space vol-
ume of mask was 100 ± 10 mL, estimated by
water displacement measured on five sub-
jects, which was not affected by mask size
used. We estimated individual physiologic
dead space using Equation 3, developed by
Harris and co-workers (28). 
VD = 0.834 (Age) + 1.26 (Height) 
+ 0.296 (VT) – 879/f – 174 [3] 
where VD = predicted physiologic dead space
volume (milliliters); Age = individual subject’s
age in years; Height = individual subject’s
height in centimeters; VT = average tidal vol-
ume in each breath (milliliters per breath);
and f = breaths every minute (breaths per
minute). This algorithm explained 89% of
the variability for the test population (R2 =
0.89) for predicting physiologic dead space
volume.
We estimated the total uptake (absorbed
BD) during exposure by the difference
between the inhaled and exhaled BD during
exposure. The total amount of inhaled BD
was estimated by the inhaled BD concentra-
tion (BDinhaled) multiplied by the alveolar
ventilation rate (V
·
A) multiplied by the dura-
tion of exposure (T). We estimated the total
amount of exhaled BD during exposure by
integrating the product of exhaled alveolar
BD concentration (BDalveolar) by V
·
A across
the period of exposure using the trapezoidal
method (29). Because BDalveolar during the
interval of 0–2 min was not measured, we
estimated its concentration as one-half the
BDalveolar measured in the first sample col-
lected during the interval of 2–3 min. We
also estimated the respiratory uptake frac-
tion—the percentage of total inhaled BD
retained in the body—by total uptake
divided by total inhaled (30–32).
Collection of exhaled breath samples and
analysis of BD. We collected mixed exhaled
breaths in Tedlar sampling bags; immediately
after testing, the collected breath was drawn
through 100/50 mg Anasorb coconut-shell
charcoal sampling tubes (No. 226-73 tubes;
SKC Inc., Eighty Four, PA). The charcoal
was pretreated with 4-tert-butylcatechol
(TBC) to prevent self-polymerization of the
collected BD (33). Charcoal tubes were
stored in a refrigerator at –20°C until analy-
sis. We used methylene chloride (99.9%;
Burdick & Jackson Inc., Muskegon, MI) to
extract BD from the charcoal. We used a
Hewlett Packard Gas Chromatograph 5890
series I (Hewlett-Packard Co., Palo Alto,
CA, USA) equipped with flame ionization
detector (FID) and an HP model 6890
autosampler to determine BD in the methyl-
ene chloride solution. The method was mod-
ified from the U.S. National Institute for
Occupational Safety and Health analytic
approach (NIOSH method 1024) (34). The
detailed analytic conditions were described
earlier in another paper (21). Finally, BD
concentration in breath samples was deter-
mined by dividing the total amount of BD
by the volume of exhaled breath. The limit of
detection was 0.006 ppm of BD in a 5.0 L
exhaled breath sample with a coefficient of
variation of 10%. 
Determination of the blood:air partition
coefficient. We determined the blood:air
partition coefﬁcient using a modiﬁcation of
the closed-vial, headspace equilibration
method (35). We spiked 50 µL of pure BD
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Milwaukee, WI) into a closed 20-mL vial
containing 6 mL of blood sample with a gas-
tight syringe (Hamilton Company, Reno,
NV). The vial was placed in a 37°C oven for
2 hr until reaching equilibrium (36). To
promote gas exchange and avoid any adsorp-
tion of BD onto the walls of the vials, we
agitated the vials occasionally using a shaker
(Lab-Line Instruments Inc., Melrose Park,
IL). We took duplicated 1-mL gas samples
after 2 hr from the headspace of the closed
vial using gas-tight syringes. We analyzed the
gas samples using gas chromatography (GC)
to determine the mass of BD in gas phase.
We calculated the amount of BD in blood
phase as the difference between the initially
added BD and the recovered BD in gas
phase, after correcting for recovery losses.
Recovery loss was the average recovery, esti-
mated from the loss of BD during the ana-
lytic procedure and from wall losses in the
empty vials; we determined the latter using
the same procedures for blood without
adding the blood sample and shaking vials.
Then we calculated the blood:air partition
coefficient as the ratio of the concentration
of BD between head-space air and blood. 
Statistical analysis. The objective of this
study was to investigate the physiologic fac-
tors that affect the respiratory uptake of BD.
We performed logarithmic transformation of
BD uptake to normalize the distribution
before regression analyses. Initially we exam-
ined separately the relationship of BD
uptake to each of the parameters of interest,
including univariate regression analyses. We
then investigated a stepwise regression model
by including interaction terms on the basis
of biologic plausibility. We examined the
assumption of linearity using residual plots
for testing the signiﬁcance of quadratic terms.
Higher-order terms are not included in the
analysis. We used the t-test, analysis of vari-
ance (ANOVA), or nonparametric Wilcoxon
rank-sum tests (if the distributions were
skewed) to compare the mean BD uptake
across race, sex, and age. We used the SAS
standard statistical package version 7.0 for
data analysis (SAS Institute Inc., Cary, NC).
The level of signiﬁcance was set at 0.05. 
Results
We tested 144 healthy individuals. We
excluded 11 subjects with incomplete data
from the ﬁnal analysis because of mask leak-
ing during the experiment (n = 6), analytic
instrument malfunction caused by saturation
of GC guard column (n = 2), lack of blood
data (n = 2), and errors in analytic prepara-
tions (n = 1). The demographic and physio-
logic characteristics of the 133 eligible
participants are summarized in Table 1. As
expected from the recruiting plan, there were
nearly equal numbers of males and females.
The ﬁnal self-reported racial distribution was
43 Caucasians (including 6 with ancestry
from the Indian subcontinent), 17 African
Americans, 27 Hispanics, and 46 Asians
(predominantly Chinese). Males and females
were significantly different for all compar-
isons of physiologic parameters (p < 0.05 for
each) such as the blood:air partition coeffi-
cient and respiratory ventilation, but we
found no significant differences in age,
smoking, and alcohol consumption. Figure 1
shows the time curve of alveolar BD concen-
tration during exposure and postexposure
phase, averaging the 133 subjects. Alveolar
BD dropped rapidly within minutes after
cessation of BD exposure and had larger
interindividual variation after exposure than
during exposure. 
The total inhaled BD during exposure
for males (301 ± 79 µg, mean ± SD) was
higher than females (275 ± 77 µg) (t-test, p =
0.04), as shown in Table 2. The total BD
uptake (absorbed BD) is also higher for
males (135 ± 50 µg) versus females (121 ±
55 µg) (Wilcoxon rank-sum test, p = 0.058).
However, the respiratory BD uptake (micro-
grams BD per kilogram of body weight) was
higher for females (2.0 ± 0.9 µg/kg) than
males (1.8 ± 0.7 µg/kg) but the difference
was not statistically significant (Wilcoxon
rank-sum test, p = 0.24). The difference
between men and women in the respiratory
uptake fraction of total inhaled, which
ranged from 18% to 74% for all 133 partici-
pants, was also not signiﬁcant. 
Univariate associations between the
physiologic factors and BD uptake (log10
transformation) found strong significant
relationships for the blood:air partition coef-
ficient and alveolar ventilation (p < 0.001)
and nonsigniﬁcant differences between sexes
(Figures 2 and 3). Current cigarette smokers
had lower respiratory BD uptake than cur-
rent nonsmokers (p = 0.02). Neither race
nor alcohol consumption was significantly
related to BD uptake (p = 0.38 and 0.31,
respectively). 
When all of the covariates were consid-
ered jointly in a multiple regression model
on log10 transformed uptake, several of the
variables became signiﬁcant (Table 3). With
the log10 transformation on BD uptake, the
model is a multivariate model where the β
values are multipliers or divisors depending
on the sign of the coefﬁcient. The blood:air
partition coefficient, alveolar ventilation,
smoking, age, and sex were all significant
predictors of the respiratory BD uptake.
Females had larger body burdens of BD per
kilogram of body weight (100.094 or 1.24
times larger) than males. Both age (9.1% loss
per decade) and smoking (smokers 18.5%
less) were negatively associated with the
uptake of BD after adjustment for the other
explanatory variables. We compared racial
groups to Caucasians as a baseline. Only
Asians showed a significantly different
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Table 1. Demographic and physiologic characteristics of 133 participants.a
Male (n = 71) Female (n = 62) 
Characteristics mean ± SD mean ± SD
Age (years) 30.3 ± 8.1 29.0 ± 8.9
Height (m) 1.74 ± 0.08 1.61 ± 0.07**
Body weight (kg) 77.7 ± 15.7 61.3 ± 15.9**
Physiologic dead space (mL)b 171.3 ± 38.9 127.5 ± 37.0**
Blood:air partition coefﬁcient 1.62 ± 0.35 1.46 ± 0.34*
Minute ventilation (L/min) 7.3 ± 1.6 6.4 ± 1.5**
Alveolar ventilation (L/min)c 3.5 ± 0.9 3.2 ± 0.8* 
Current smoking, n (%) 
Yes 14 (20) 9 (15)
No 57 (80) 53 (85)
Alcohol consumption (drinks/week in the past year),d n (%) 
> 2  27 (38) 16 (26)
1–2 24 (34) 26 (42)
0 20 (28) 20 (32)
aWe made sex comparisons using t-tests for continuous variables and chi-square tests for categoric variables; we used
Wilcoxon rank-sum tests for age, weight, physiologic dead space, and minute ventilation because of skewness in these
variables. bEstimated from prediction formula (28). cEstimated from minute ventilation by adjusting for individual physio-
logic and mask dead space (100 mL). dA drink was deﬁned as 12 oz of beer, 5 oz of wine, or 1.5 oz of hard liquor (20). *p <
0.05; **p < 0.01.
Figure 1. Time course of mean alveolar BD (loga-
rithm scale) during exposure and postexposure
phases summarized for 133 subjects exposed to 2
ppm BD for 20 min, followed by clean air for
another 40 min; error bars represent 1 SD.
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2 ppm BD exposure Postexposure (clean air)uptake than Caucasians (19.9% higher).
Alcohol consumption did not predict the
outcome variable in the multivariate model.
We retained both race and alcohol con-
sumption in the final multiple regression
model to adjust for the confounding effects,
and we found no signiﬁcant interactions or
nonlinear terms (data not shown). 
Discussion 
Our ﬁndings were consistent with the previ-
ous PBPK model simulations that showed
that alveolar ventilation and the blood:air
partition coefficient were two of the most
important physiologic factors in predicting
the respiratory uptake of BD (26). In addi-
tion, females had higher respiratory BD
uptake (micrograms per kilogram) than
males after adjustment for body weight and
the other explanatory variables. The sex dif-
ference in respiratory BD uptake may result
partly from differences in the fat composi-
tion of body compartments, indicated by the
ratio of fat/lean body mass. The fatty tissue
can extract and store lipophilic chemicals
more effectively, which contributes to reten-
tion of absorbed lipophilic chemicals during
and after exposure (37). Previous studies of
different racial populations had consistently
indicated that the fat compartment is signiﬁ-
cantly larger in females than males, but the
magnitude of body fat varied across ethnic
groups (38–40). A better method for esti-
mating body fat is needed for pharmacoki-
netic studies. 
Increased age and current cigarette smok-
ing were associated with decreasing respira-
tory uptake of BD after adjustment for the
other factors. Age and smoking effects might
both decrease pulmonary gas exchange effi-
ciency, which might also reduce the respira-
tory uptake of BD (41,42). Although
reasonable, this must be demonstrated with
further testing and concurrent measurement
of gas exchange efﬁciency.
The observed uptake of BD is caused by
solubility in the blood, retention in fat and
other tissues, and metabolism. BD is rapidly
taken up and released by vessel-rich tissues,
and more slowly by poorly perfused tissues.
Within the time scale of the experimental
exposure, all of the BD in blood passing
through the body fat will be retained and
only very slowly be released during or after
exposure. However, the blood ﬂow through
the fat is only a small fraction of the total,
5%–9% (43). A small amount of the BD
inhaled is exhaled after exposure stops, as BD
is rapidly cleared from most of the tissues.
Because of fat retention and slow distrib-
ution to and from the poorly perfused tissues
on the short time scale of the experimental
exposure, if there was no metabolism,
approximately 10%–20% of the inhaled BD
would not be exhaled during the exposure
period. The average percent retained by the
subjects ranged from 18% to 74%, which
strongly implies that some individuals metab-
olized a signiﬁcant quantity of BD. Mezzetti
and coworkers (23) did pharmacokinetic
modeling with the exhaled breath data to
estimate BD metabolism. This modeling
found large population variability for the
metabolism rate, which was much larger than
the uncertainty in model fitting. Estimated
clearance values for some individuals
(approximately 20% of the total) exceeded
the likely total blood ﬂow of the liver.
In the current study, all of the subjects
received the same administered dose, 2.0
ppm for 20 min. The wide range of BD
uptake clearly shows that administered dose
is a poor estimator of the absorbed dose,
even absorbed dose per kilogram of body
weight. Because signiﬁcant effects on uptake
were observed for age, sex, and smoking,
these factors are likely to be important modi-
fiers of risk from exposure to BD. The BD
Articles • Lin et al.
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Table 2. Respiratory uptake of BD in humans exposed to 2 ppm BD for 20 min.a
Male (n = 71) Female (n = 62)
Uptake Mean ± SD Mean ± SD
Total inhaled BD (µg)b 301 ± 79 275 ± 77*
Total uptake (absorbed BD) (µg)c 135 ± 50 121 ± 55
Respiratory uptake of BD 1.8 ± 0.7 2.0 ± 0.9
(µg BD absorbed/kg body weight)d
Respiratory uptake fraction (%)e 45.6 ± 13.9 43.4 ± 2.9 
aWe made sex comparisons using t-tests; we used Wilcoxon rank-sum tests for total uptake and respiratory uptake of
BD because of skewness in these variables. bWe based the calculation on alveolar ventilation; 1 ppm BD = 2.21 µg BD/L
at room temperature and atmosphere pressure. cThe difference between total inhaled BD and total exhaled BD during
exposure. dRespiratory uptake of BD was derived from absorbed BD divided by body weight. ePercentage of total inhaled
BD absorbed, equal to absorbed BD*100% /total inhaled BD. *p < 0.05 
Table 3. Multiple regression of log10 transformed respiratory uptake of BDa,b (n = 133).
Explanatory variables β (SE) p-Value  
Blood:air partition coefﬁcient 0.172 (0.039) < 0.001
Alveolar ventilation (L/min) 0.102 (0.017) < 0.001
Age (years) –0.004 (0.002) 0.03
Sex (female = 1, male = 0) 0.094 (0.027) < 0.001
Current smoking (yes = 1, no = 0) –0.089 (0.036) 0.01
Racec
African American –0.004 (0.043) 0.93
Hispanic 0.046 (0.039) 0.24
Asian 0.079 (0.036) 0.03
Caucasian Reference
Alcohol consumptiond (drinks/week during the past year)
> 2 0.028 (0.036) 0.45
1–2 0.019 (0.032) 0.55
0 Reference
aRespiratory uptake of BD: micrograms BD absorbed per kilogram body weight during exposure. bR2 and adjusted R2
for the multivariate regression model were 0.41 and 0.36, respectively. cOverall race is not signiﬁcant in the multi-
variate model (F3,122 = 1.96, p = 0.12). dOverall alcohol consumption is not signiﬁcant in the multivariate model (F2,122
= 0.31, p = 0.73).
Figure 2. The relationship of respiratory uptake of
BD to blood:air partition coefficient by sex. bw,
body weight. The difference in slopes between
sexes is not statistically signiﬁcant (p= 0.61). 
Figure 3. The relationship of respiratory uptake of
BD to alveolar ventilation by sex. bw, body
weight. The difference in slopes is not statisti-
cally signiﬁcant (p = 0.11). 
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Regression line, maleuptake is an absorbed dose, but it is not a
measure of biologically effective dose because
BD must be metabolized to active epoxides
and perhaps other materials to cause adverse
effects. However, the absorbed dose is a major
limit to the quantity of active agents that may
be formed. Estimation of physiologic factors
as rate limiting steps for internal dose has
received little attention by risk assessors. Our
study clearly shows the importance of
including consideration of variation in
uptake in risk assessment. 
There were two major limitations in the
current study. First, it was not practical to
collect data on cardiac output. Cardiac out-
put is an inﬂuential factor in the inhalation
kinetics of gases and vapors in humans, espe-
cially for less soluble chemicals (44,45). In
contrast, alveolar ventilation is more impor-
tant for highly soluble gases. The blood:air
partition coefficient was critical for both
highly and less lipid soluble chemicals (46).
BD has an intermediate lipid solubility,
compared to the commonly used anesthetics
(47), so both cardiac output and alveolar
ventilation are important. This is reﬂected in
the positive relationship of BD uptake with
the blood:air partition coefﬁcient and alveo-
lar ventilation, but the strength of the rela-
tionships might be improved with data on
cardiac output. Further investigations that
include cardiac output measurement are
needed to clarify this assumption. 
The second limitation was lack of
direct measurement of alveolar BD. In this
inhalation study, the alveolar BD was esti-
mated from mixed exhaled breath by adjust-
ing for the total dead space. Physiologic dead
space was estimated using a highly predictive
model (R2 = 0.89) and the mask dead space
was measured. With the extra dead space
from the mask, the total was nearly as large
as the alveolar volume. As a result, errors in
the estimation of dead space and variation in
the relative amount of dead space with depth
of inhalation will add error to the estimates
of both alveolar ventilation rate and alveolar
BD concentration. Absorption and release of
BD in the upper airways was assumed to be
negligible because BD has a low water solu-
bility (48,49). Thus, an important source of
measurement error in estimating alveolar
BD was the uncertainty in estimating physi-
ologic dead space. An improvement in the
estimation of the alveolar BD concentration
could be obtained with real-time measure-
ment of exhaled BD in breath; then the con-
centration in end-exhalation alveolar gases
could be measured directly.
In summary, this study found that physi-
ologic parameters play an important role in
determining BD uptake, which will subse-
quently affect the risk from exposure to BD.
Thus, it is necessary to consider variability in
physiologic factors across populations to pro-
ject risk from these exposures in the work-
place and urban air pollution. In addition, it
is also likely that the physiologic factors may
also change within the same individual across
time, such as increased respiratory ventilation
caused by physical workload and a decline
with age. Thus, we recommend that future
epidemiologic work account for physiologic,
environmental, and metabolic variability
whenever possible to detect and quantify dif-
ferences in the factors that affect the relation-
ships between exposure and internal dose.
These factors may also identify previously
unrecognized sensitive subpopulations with
potentially increased risk. There may be pol-
icy limitations that prevent development of
separate exposure standards for more sensi-
tive subgroups, but these populations should
be considered when assessing the adequacy of
proposed standards for exposure.
REFERENCES AND NOTES
1.  Rego A, Roley L. In-use barrier integrity of gloves: latex
and nitrile superior to vinyl. Am J Infect Control
27:405–410 (1999).
2.  Fajen JM, Roberts DR, Ungers LJ, Krishnan ER.
Occupational exposure of workers to 1,3-butadiene.
Environ Health Perspect 86:11–18 (1990).
3.  U.S. EPA. Non-Methane Organic Compound Monitoring
Program-Final Report. EPA/450/1-90/004b. Washington,
DC:U.S. Environmental Protection Agency, 1989.
4.  Melnick RL, Huff J. 1,3-Butadiene: toxicity and carcino-
genicity in laboratory animals and in humans. Rev
Environ Contam Toxicol 124:111–144 (1992).
5.  Himmelstein MW, Acquavella JF, Recio L, Medinsky MA,
Bond JA. Toxicology and epidemiology of 1,3-butadiene.
Crit Rev Toxicol 27:1–108 (1997).
6.  Divine BJ, Wendt JK, Hartman CM. Cancer mortality
among workers at a butadiene production facility. IARC
Sci Pub 127:345–362 (1993).
7.  Melnick RL, Shackelford CC, Huff J. Carcinogenicity of 1,3-
butadiene. Environ Health Perspect 100:227–236 (1993).
8.  Cole P, Delzell E, Acquavella J. Exposure to butadiene
and lymphatic and hematopoietic cancer. Epidemiology
4:96–103 (1993).
9.  Ward EM, Fajen JM, Ruder AM, Rinsky RA, Halperin WE,
Fessler-Flesch CA. Mortality study of workers in 1,3-
butadiene production units identified from a chemical
workers cohort. Environ Health Perspect 103:598–603
(1995).
10.  Schulte PA, Perera FP. Molecular epidemiology: princi-
ples and practices. In: Biological Monitoring and
Pharmacokinetic Modeling for the Assessment of
Exposure (Pierre OD, ed). San Diego, CA:Academic Press,
1993;137–157.
11.  Baskin LB, Falco JW. Assessment of human exposure to
gaseous pollutants. Risk Anal 9:365–375 (1989).
12.  Johanson G, Filser JG. PBPK model for butadiene metab-
olism to epoxides: quantitative species differences in
metabolism. Toxicology 113:40–47 (1996).
13.  Gargas ML, Andersen ME, Clewell HJ III. A physiologi-
cally based simulation approach for determining meta-
bolic constants from gas uptake data. Toxicol Appl
Pharmacol 86:341–352 (1986).
14.  Dahl AR, Sun JD, Birnbaum LS, Bond JA, Grifﬁth WC Jr,
Mauderly JL, Muggenburg BA, Sabourin PJ, Henderson
RF. Toxicokinetics of inhaled 1,3-butadiene in monkeys:
comparison to toxicokinetics in rats and mice. Toxicol
Appl Pharmacol 110:9–19 (1991).
15.  Csanady GA, Kreuzer PE, Baur C, Filser JG. A physiologi-
cal toxicokinetic model for 1,3-butadiene in rodents and
man: blood concentrations of 1,3-butadiene, its metaboli-
cally formed epoxides, and of haemoglobin adducts—rel-
evance of glutathione depletion. Toxicology 113:300–305
(1996).
16.  Dahl AR, Bechtold WE, Bond JA, Henderson RF,
Mauderly JL, Muggenburg BA, Sun JD, Birnbaum LS.
Species differences in the metabolism and disposition of
inhaled 1,3-butadiene and isoprene. Environ Health
Perspect 86:65–69 (1990).
17.  Bond JA, Recio L, Andjelkovich D. Epidemiological and
mechanistic data suggest that 1,3-butadiene will not be
carcinogenic to humans at exposures likely to be encoun-
tered in the environment or workplace. Carcinogenesis
16:165–171 (1995).
18.  Sweeney LM, Schlosser PM, Medinsky MA, Bond JA.
Physiologically based pharmacokinetic modeling of 1,3-
butadiene, 1,2-epoxy-3-butene, and 1,2:3,4-diepoxybu-
tane toxicokinetics in mice and rats. Carcinogenesis
18:611–625 (1997).
19.  Air Resources Board. Proposed Identification of 1,3-
Butadiene as a Toxic Air Contaminant. Sacramento,
CA:California Environmental Protection Agency, 1992.
20.  Nutrition and Your Health: Dietary Guidelines for
Americans. 4th ed. HG 232. Washington, DC:U.S. Dept. of
Health and Human Services, U.S. Department of
Agriculture, 1995. Available at: http://www.nalusda.gov/
fnic/dga/dga95/cover.html (cited 20 July 2001).
21.  Lin YS, Smith TJ, Wang PY. Unpublished data.
22.  Bois FY, Smith TJ, Gelman A, Chang HY, Smith AE.
Optimal design for a study of butadiene toxicokinetics in
humans. Toxicol Sci 49:213–224 (1999).
23.  Mezzetti M, Ibrahim JG, Bois FY, Smith TJ, Ryan L.
Bayesian compartmental model for evaluation of 1,3-
butadiene biomarkers. Unpublished data.
24.  Munson ES, Eger EId, Tham MK, Embro WJ. Increase in
anesthetic uptake, excretion, and blood solubility in man
after eating. Anesth Analg 57:224–231 (1978).
25.  Groeseneken D, Veulemans H, Masschelein R.
Respiratory uptake and elimination of ethylene glycol
monoethyl ether after experimental human exposure. Br
J Ind Med 43:544–549 (1986).
26.  Kohn MC, Melnick RL. Species differences in the produc-
tion and clearance of 1,3-butadiene metabolites: a mech-
anistic model indicates predominantly physiological, not
biochemical, control. Carcinogenesis 14:619–628 (1993).
27.  U.S. Food and Drug Administration, Center for Drug
Evaluation and Research (CDER). Guidance for Industry:
Population Pharmacokinetics. Available: http://
www.fda.gov/cder/guidance/1852fnl.pdf [cited 16
February 2001].
28.  Harris EA, Seelye ER, Whitlock RM. Revised standards for
normal resting dead-space volume and venous admixture
in men and women. Clin Sci Mol Med 55:125–128 (1978).
29.  Fiserova-Bergerova V. Introduction to mathematical
model. In: Modeling of Inhalation Exposure to Vapors:
Uptake, Distribution, and Elimination, Vol 1 (Fiserova-
Bergerova V, ed). Boca Raton, FL:CRC Press, 1983;51–70.
30.  Opdam JJ. Respiratory input in inhalation experiments.
Br J Ind Med 46:145–156 (1989).
31.  Johanson G, Boman A. Percutaneous absorption of 2-
butoxyethanol vapour in human subjects. Br J Ind Med
48:788–792 (1991).
32.  Nihlen A, Lof A, Johanson G. Controlled ethyl tert-butyl
ether (ETBE) exposure of male volunteers. I.
Toxicokinetics. Toxicol Sci 46:1–10 (1998).
33.  SKC Product Home Page. Air Sampling: Sampling 
Tubes with Treated Sorbents. Available: http://
www.skcinc.com/prod/treated.html [cited 16 February
2001].
34. Lunsford RA, Gagnon YT, Palassis J. NIOSH Manual of
Analytical Methods. 4th ed. NIOSH Publication no. 
94-113. Cincinnati, OH:National Institute for 
Occupational Safety and Health, 1994. Available:
http://www.cdc.gov/niosh/pdfs/1024.pdf (cited 20 July
2001).
35.  Fiserova-Bergerova V, Tichy M, Di Carlo FJ. Effects of
biosolubility on pulmonary uptake and disposition of
gases and vapors of lipophilic chemicals. Drug Metab
Rev 15:1033–1070 (1984).
36.  Chang H-Y. Bioindicator of 1,3-Butadiene Exposure [ScD
Thesis]. Boston:Harvard University, 1996.
37.  Geyer HJ, Scheunert I, Rapp K, Gebefugi I, Steinberg C,
Kettrup A. The relevance of fat content in toxicity of
lipophilic chemicals to terrestrial animals with special
reference to dieldrin and 2,3,7,8- tetrachlorodibenzo-p-
dioxin (TCDD). Ecotoxicol Environ Saf 26:45–60 (1993).
38.  Deurenberg P, van der Kooy K, Leenen R, Weststrate JA,
Seidell JC. Sex and age speciﬁc prediction formulas for
Articles • Human physiologic factors in butadiene uptake
Environmental Health Perspectives • VOLUME 109 | NUMBER 9 | September 2001 925estimating body composition from bioelectrical imped-
ance: a cross-validation study. Int J Obes 15:17–25 (1991).
39.  Sato A, Endoh K, Kaneko T, Johanson G. A simulation
study of physiological factors affecting pharmacokinetic
behaviour of organic solvent vapours. Br J Ind Med
48:342–347 (1991).
40.  Goran MI, Allison DB, Poehlman ET. Issues relating to
normalization of body fat content in men and women. Int
J Obes Relat Metab Disord 19:638–643 (1995).
41.  Stankus RP, Menon PK, Rando RJ, Glindmeyer H,
Salvaggio JE, Lehrer SB. Cigarette smoke-sensitive
asthma: challenge studies. J Allergy Clin Immunol
82:331–338 (1988).
42.  Oldigs M, Jorres R, Magnussen H. Acute effect of 
passive smoking on lung function and airway respon-
siveness in asthmatic children. Pediatr Pulmonol
10:123–131 (1991).
43.  Saidman LJ. Anethesia at a constant alveolar ventilation.
In: Modeling of Inhalation Exposure to Vapors: Uptake,
Distribution, and Elimination, Vol 2 (Fiserova-Bergerova
V, ed). Boca Raton, FL:CRC Press, 1983;131–143.
44.  Janosa AD, Zbinden AM, Feigenwinter P. Simulation of
inhalational anaesthetic uptake using a lung model with
charcoal. Acta Anaesthesiol Scand 38:672–678 (1994).
45.  Stoelting RK. Pharmacology and Physiology in Anesthetic
Practice. 3rd ed. Philadelphia:Lippincott-Raven, 1999.
46.  Rozman KK, Klaassen CD. Absorption, distribution, and
excretion of toxicants. In: Casarett and Doull’s Toxicology:
The Basic Science of Poisons (Casarett LJ, Klaassen CD,
Amdur MO, Doull J, eds). New York:McGraw-Hill Health
Professions Division, 1996;91–112.
47.  Yasuda N, Targ AG, Eger EId. Solubility of I-653, sevoﬂu-
rane, isoﬂurane, and halothane in human tissues. Anesth
Analg 69:370–373 (1989).
48. Medinsky MA, Sabourin PJ, Lucier G, Birnbaum LS,
Henderson RF. A physiological model for simulation of
benzene metabolism by rats and mice. Toxicol Appl
Pharmacol 99:193–206 (1989).
49.  Hansch C, Hoekman D, Leo A, Zhang L, Li P. The expand-
ing role of quantitative structure-activity relationships
(QSAR) in toxicology. Toxicol Lett 79:45–53 (1995).
Articles • Lin et al.
926 VOLUME 109 | NUMBER 9 | September 2001 • Environmental Health Perspectives